Tadalafil Side Effects

Reported Tadalafil side effects

Tadalafil has a well-characterized safety profile from more than two decades of post-approval use in millions of patients. Common side effects are typically mild, transient, and dose-related. Most common side effects (>5% incidence): Headache: Occurs in 10-15% of users, typically mild, usually resolves with continued use or with dose reduction. Not typically severe enough to warrant discontinuation. Dyspepsia (indigestion, stomach upset): 5-10% of users, mild, often improves with continued use. Taking with or without food does not substantially alter this effect. Back pain and muscle pain: 3-8% of users, typically mild, usually resolves within 12-48 hours of dose. More common with tadalafil than with other PDE5 inhibitors, possibly related to PDE11 inhibition in skeletal muscle. Often responds to dose reduction. Nasal congestion: 3-5% of users, mild and transient. Due to nasal mucosal vasodilation. Flushing: 2-4% of users, mild, transient. Limb pain: 3-5% of users, typically mild. Less common side effects: Dizziness, blurred vision (transient, not the color vision changes seen with sildenafil), abdominal pain, diarrhea, cough, nausea. Uncommon but clinically significant: Priapism (prolonged, painful erection > 4 hours): Rare (<0.01%) but medical emergency requiring immediate emergency department evaluation. Untreated priapism can cause permanent erectile tissue damage. Risk is higher with: injection use of other vasoactive agents (not applicable for oral tadalafil); sickle cell disease or trait; leukemia; other conditions affecting erectile tissue. NAION (non-arteritic ischemic optic neuropathy): Very rare (estimated <1 in 100,000 users) but serious. Can cause sudden partial or complete vision loss, usually unilateral. Risk factors: age >50, hypertension, diabetes, hyperlipidemia, smoking, "crowded disc" (small optic cup). Post-marketing class-label warning for all PDE5 inhibitors. Any new visual disturbance warrants immediate discontinuation and ophthalmologic evaluation. Sudden hearing loss: Very rare; typically unilateral, may be partial or complete. Tinnitus and vertigo often accompany. Post-marketing class-label warning. Immediate discontinuation and medical evaluation if occurring. Serious cardiovascular events: Myocardial infarction, stroke, serious cardiac arrhythmia. Background rate in population at risk for ED and BPH is elevated; PDE5 inhibitor contribution above background is controversial and likely small-to-none. Important: serious cardiovascular events during sexual activity are a known risk attributable to the activity itself, not to PDE5 inhibitors specifically. Hypotension: Modest blood pressure reduction (2-6 mmHg systolic) is expected pharmacodynamic effect. Clinically significant hypotension (requiring intervention) is uncommon with monotherapy but a serious concern with specific drug interactions. Critical Drug Interaction: Nitrates: ABSOLUTE CONTRAINDICATION for concurrent use. Nitrates (nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, amyl nitrite, other organic nitrates) work through NO-cGMP pathway; combined with tadalafil's PDE5 inhibition (which amplifies cGMP signaling), the result is profound hypotension that can be life-threatening. This applies to all forms of nitrates — oral, sublingual, transdermal, intravenous, inhaled, recreational. Tadalafil must not be used within 48 hours of nitrate use (shorter-acting nitrates like nitroglycerin spray) or with any chronic nitrate therapy. For patients with chest pain (potential angina) who are taking tadalafil, nitrates cannot be used in emergency treatment; alternative anti-anginal treatment (beta-blocker, calcium channel blocker) is required. This interaction extends at least 48 hours after last tadalafil dose due to tadalafil's long half-life. Alpha-blocker interaction: Alpha-1 adrenergic antagonists (tamsulosin, alfuzosin, doxazosin, terazosin, silodosin) produce orthostatic hypotension through direct vasodilation. Combined with tadalafil, the additive vasodilatory effect can produce clinically significant orthostatic symptoms including dizziness, presyncope, or syncope. Recommendations: 1) Tamsulosin 0.4 mg and silodosin 8 mg are the alpha-blockers with least interaction concerns with tadalafil at daily low-dose (2.5-5 mg), making these combinations relatively safe; 2) Doxazosin, terazosin, and alfuzosin have more potential for orthostasis with tadalafil; separate dosing by 4+ hours and titrate cautiously; 3) On-demand tadalafil (10-20 mg) combined with alpha-blocker requires caution; consider stable alpha-blocker dose before adding on-demand tadalafil. CYP3A4 Inhibitor interactions: Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, atazanavir, grapefruit juice regular consumption, nefazodone) substantially elevate tadalafil levels. Ketoconazole 400 mg daily increases tadalafil AUC approximately 14-fold. Dose adjustment: maximum 10 mg tadalafil every 72 hours during concurrent strong CYP3A4 inhibitor use (or avoid combination). Moderate CYP3A4 inhibitors (fluconazole, erythromycin, diltiazem, verapamil): dose reduction to 5 mg maximum and less frequent dosing reasonable. CYP3A4 Inducer interactions: Strong inducers (rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort) substantially reduce tadalafil levels. Effect may be inadequate therapeutic response; consider alternative therapy or dose adjustment. Antihypertensive interactions: Beyond alpha-blockers, other antihypertensives (beta-blockers, ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics) produce modest additive blood pressure reduction with tadalafil. Usually clinically manageable without dose adjustment, but monitor for orthostatic symptoms. Amiodarone, class III antiarrhythmics: QT prolongation concerns; combination requires cardiology assessment. Tadalafil itself does not significantly prolong QT interval at therapeutic doses. Specific population considerations: Elderly (>65): Increased exposure due to reduced clearance; dose adjustment usually not required but start at lower dose. Renal impairment: Mild-moderate (CrCl 30-80): no adjustment for on-demand use; daily use start at 2.5 mg. Severe (CrCl <30): daily use not recommended; on-demand maximum 5 mg and limit frequency. Dialysis: maximum 5 mg on-demand. Hepatic impairment: Mild-moderate (Child-Pugh A-B): maximum 10 mg on-demand. Severe (Child-Pugh C): not recommended. Concurrent PDE5 inhibitor use: Do not combine tadalafil with other PDE5 inhibitors (sildenafil, vardenafil, avanafil). No additive efficacy benefit; additive adverse effect risk. Alcohol: Moderate alcohol (1-2 drinks) is generally compatible with tadalafil. Heavier alcohol use can compound hypotension, headache, and dyspepsia. Other recreational substances: "Poppers" (amyl nitrite, isobutyl nitrite, recreational inhalant nitrates) are nitrates and produce the severe hypotension interaction. Cocaine combined with tadalafil may stress cardiovascular system. MDMA ("Molly") with tadalafil combines cardiovascular stressors and serotonergic effects. Priapism risk factors: Sickle cell disease or trait, leukemia, multiple myeloma, other blood dyscrasias, cavernosal fibrosis, Peyronie's disease (modest), concurrent intracavernosal vasoactive medications (alprostadil, papaverine). Any sustained erection >4 hours requires emergency evaluation. Surgical considerations: For elective surgery with potential for hypotension (cardiac, vascular, major abdominal), consider withholding tadalafil for 48-72 hours before surgery. Emergency surgery with recent tadalafil use: inform anesthesiology team; implications for nitrate availability in perioperative hypertensive crisis management. Overdose: Limited data on massive overdose. Expected features: severe headache, flushing, back pain, myalgia, dyspepsia, dizziness, possible hypotension. Management is supportive. Hemodialysis has limited value given tadalafil's high protein binding. Controlled substance / regulatory status: Tadalafil is a prescription medication (Rx-only) in the US, Canada, EU, UK, Australia, and most developed countries. Over-the-counter availability exists in some jurisdictions (Sweden, UK via pharmacist consultation). Gray-market purchase (online without prescription) carries quality, counterfeit, and regulatory risk. Quality/Counterfeit Concerns: Counterfeit tadalafil is a significant market issue, particularly with online purchases from unverified sources. Counterfeits may contain: no active ingredient, incorrect dose, contaminants, heavy metals, or other drugs (including sildenafil). Use only legitimate pharmacy sources. Aminotadalafil distinction: The research chemical analog aminotadalafil is structurally distinct from tadalafil, has no FDA approval, lacks manufacturing quality control standards, and is sold as a research chemical with marketing explicitly or implicitly encouraging human consumption — a regulatory gray zone with safety concerns. Actual tadalafil from legitimate pharmacy sources is a well-established prescription medication with substantially better safety and quality assurance.

When to continue, reduce, or stop Tadalafil

Tadalafil contraindications

Tadalafil has well-defined contraindications and populations requiring caution. Absolute Contraindications: Concurrent nitrate use: Tadalafil must NOT be used with any form of nitrate medication (nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, amyl nitrite, other organic nitrates). This applies to oral, sublingual, transdermal (patches), intravenous, inhaled, and recreational nitrates. The combination produces severe, potentially fatal hypotension. Tadalafil's long half-life extends this contraindication to at least 48 hours after last tadalafil dose before nitrate use, and at least 72 hours between nitrate use and resuming tadalafil. Concurrent guanylate cyclase stimulators (riociguat): Absolute contraindication due to additive effect on cGMP pathway producing severe hypotension. Applies to riociguat (Adempas) used for PAH and CTEPH. Recent cardiac event: Myocardial infarction within 90 days, unstable angina, angina during sexual intercourse, NYHA class II or greater heart failure in the past 6 months, uncontrolled arrhythmias, hypotension (BP <90/50), uncontrolled hypertension (BP >170/100), stroke within 6 months. These are situations where cardiovascular demands of sexual activity or potential tadalafil effects preclude use. Known hypersensitivity to tadalafil or excipients. Retinitis pigmentosa (hereditary retinal disorder): Small number of patients have phosphodiesterase disorders as cause; tadalafil is contraindicated or use with extreme caution. Previous NAION (non-arteritic ischemic optic neuropathy): Contraindication to future PDE5 inhibitor use. Relative Contraindications and Cautions: Alpha-blocker use: Requires stable alpha-blocker dosing and careful titration. Tamsulosin 0.4 mg and silodosin 8 mg have least interaction; doxazosin, terazosin, alfuzosin require more caution. Strong CYP3A4 inhibitors: Ketoconazole, itraconazole, clarithromycin, ritonavir, atazanavir, grapefruit juice consumption. Dose adjustment required (maximum 10 mg every 72 hours on-demand). Severe renal impairment (CrCl <30): Daily regimen not recommended. Severe hepatic impairment (Child-Pugh C): Avoid. Age <18: Not indicated for pediatric use. Women: Not approved for female sexual dysfunction (trials have been inconclusive). Not indicated in women of reproductive age except for PAH indication. Pregnancy: Category B. Tadalafil crosses placenta. Limited human data; animal studies do not show teratogenicity. Not indicated in women except rare PAH context. Breastfeeding: Limited data; avoid unless specific indication. Blood dyscrasias predisposing to priapism: Sickle cell disease or trait, leukemia, multiple myeloma. Use with caution; priapism is medical emergency. Peyronie's disease or cavernosal fibrosis: Not contraindication but alters risk-benefit. Current alcohol use disorder: Caution with concurrent alcohol use; cardiovascular risk during sexual activity with substance abuse. Bleeding disorders or active peptic ulcer disease: No specific contraindication but caution; tadalafil has minor effects on platelet function. Concurrent use with other PDE5 inhibitors: Not safe; no additive efficacy, additive side effects. Medication Interactions (Critical): Nitrates: Absolute contraindication as described. Guanylate cyclase stimulators: Absolute contraindication. Strong CYP3A4 inhibitors: Dose reduction required. Alpha-blockers: Careful titration; specific alpha-blocker choice important. CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's Wort): Reduce efficacy. Medication Interactions (Moderate): Antihypertensives: Generally compatible with modest additive BP effect. Antidepressants: Most SSRIs, SNRIs, TCAs compatible. Antiarrhythmics (amiodarone, other class III): Cardiology assessment; QT considerations. Anticoagulants: Warfarin — no significant interaction; DOACs — modest CYP3A4 concerns with some agents but usually clinically manageable. HIV protease inhibitors (ritonavir, atazanavir, others): Significant CYP3A4 interaction; dose reduction required. Antifungals (ketoconazole, itraconazole, voriconazole): Significant CYP3A4 interaction. Macrolides (clarithromycin, erythromycin): CYP3A4 interaction (clarithromycin more than erythromycin). Calcium channel blockers (diltiazem, verapamil): Moderate CYP3A4 inhibition; modest interaction. Special populations: Elderly: Modestly reduced clearance; standard dose adjustment usually not required. Diabetes: Response to PDE5i somewhat reduced in severe diabetes; higher doses often needed; safety profile unchanged. Cardiovascular disease (without active events or nitrate use): Generally safe; assess exercise capacity (can patient manage ~5-6 METs?). Men with history of priapism or prolonged erections: Use cautiously; lower dose; educate on emergency response. Hearing impairment: Monitor for sudden hearing changes. Visual impairment or known retinal disease: Monitor; NAION risk. Depression and psychiatric illness: Generally compatible; antidepressant-induced sexual dysfunction is common indication. Symptoms warranting immediate medical attention: Sudden vision changes (loss of vision, color vision changes, blurred vision) — stop and seek evaluation; sudden hearing loss or tinnitus — stop and seek evaluation; priapism (erection >4 hours) — emergency department immediately; chest pain — emergency evaluation, do NOT use nitrates for at least 48 hours; severe headache not responsive to usual measures; allergic reactions. Perioperative considerations: Elective surgery with potential hypotension: hold tadalafil 72 hours before. Emergency surgery: inform anesthesia team (affects nitrate availability). Substance use: "Poppers" (amyl nitrite) — absolute contraindication. Other recreational drugs: cardiovascular stressors; caution. Monitoring: Initial cardiovascular assessment; periodic review of efficacy and tolerance; specific lab monitoring not required for uncomplicated use. Annual cardiovascular risk assessment appropriate for chronic use. Quality and counterfeit concerns: Only use tadalafil from legitimate pharmacy sources. Counterfeit products are common and dangerous. Verify source and packaging. Aminotadalafil distinction: Aminotadalafil is a structurally-distinct research chemical analog without FDA approval, quality control, or established safety profile. Not equivalent to tadalafil.

Why vendor quality drives Tadalafil side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Tadalafil side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .